Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

enVVeno Medical Corporation NVNO NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
59/100
3/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

enVVeno Medical Corporation (NVNO) is a Medical - Devices company in the Healthcare sector, currently trading at $11.00. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Valuation: NVNO trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.

Net income is $19M (loss), growing at +7.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $700,000 against $27M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 13.58 (strong liquidity). Debt-to-assets is 2.4%. Total assets: $30M.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 65/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

NVNO SharesGrow Score Overview

73/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 65/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NVNO

✓
VALUE Pass
100/100
NVNO trades at a trailing Price-to-Earnings (P/E) of -0.3 (S&P 500 average ~25). Forward PEG 0.01 — Peter Lynch undervalued (≤1.0). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
65/100
NVNO: +0%/yr revenue is, +7.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet NVNO: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 13.58 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NVNO: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range8.67-196.7
Volume4.95K
Avg Volume (30D)21.77K
Market Cap$181.53K
Beta (1Y)1.09
Share Statistics
EPS (TTM)-33.06
Shares Outstanding$589K
IPO Date2018-05-31
Employees37
CEORobert A. Berman
Financial Highlights & Ratios
Gross Profit$-489K
EBITDA$-20.41M
Net Income$-19.47M
Operating Income$-20.9M
Total Cash$28.21M
Total Debt$700K
Net Debt$-2.37M
Total Assets$29.56M
Price / Earnings (P/E)-0.3
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS29415J2050

Price Chart

Track all markets on TradingView
NVNO
enVVeno Medical Corporation ↗  ·  NASDAQ Capital Marke
Healthcare • Medical - Devices
8.67 52WK RANGE 196.70

People Also View

LIVN
LIVN
LivaNova PLC
$64.99
+0.63%
 AXGN
AXGN
AxoGen, Inc.
$34.46
+2.96%
 SRDX
SRDX
Surmodics, Inc.
$42.98
+0.35%
 OFIX
OFIX
Orthofix Medical Inc.
$12.72
+0.55%
 KIDS
KIDS
OrthoPediatrics Corp.
$17.86
+5.37%
 RXST
RXST
RxSight, Inc.
$7.27
+3.12%
 ELMD
ELMD
Electromed, Inc.
$25.21
+1.04%
 TMCI
TMCI
Treace Medical Concepts, Inc.
$2.13
+5.97%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message